Table 1.
Characteristics of the study population (n = 987)
| Age (years) (range) | 61 (24–94) |
|---|---|
| Male sex | 800 (81) |
| Current smokers | 474 (48) |
| Previous CVD | 229 (23) |
| Treated hypertension | 334 (34) |
| Treated diabetes mellitus | 124 (12) |
| BMI (kg/m2) | 26.6 (24.3,29.2) |
| Prehospital thrombolysis | 119 (12) |
| Aspirin | 231 (23) |
| Statins | 233 (23) |
| Total cholesterol (mmol/L) | 4.9 (4.1,5.6) |
| HDL (mmol/L) | 1.06 (0.88,1.30) |
| Triglycerides (mmol/L) | 1.25 (0.89,1.78) |
| CRP (mg/L) | 13.4 (7.0,31.3) |
| Admission glucose (mmol/L) | 7.4 (6.3,9.0) |
| Fasting glucose (mmol/L) | 5.8 (5.2,6.6) |
| HbA1c (%) | 5.9 (5.6,6.3) |
| Peak Troponin T (ng/L) | 3850 (1710,7250) |
| NT-ProBNP (pmol/L) | 31 (10,118) |
| LV Ejection fraction (%) | 50 (44,55) |
| D-dimer (ng/mL) | 456 (287,796) |
| F1 + 2 (pmol/L) | 246 (178,356) |
| ETP (nM⋅min) | 1564 (1366,1743) |
| Time from onset of symptoms to blood sampling (hours) (range) | 24 (5–118) |
Number (proportions) or median (25,75 percentiles) are given
BMI Body mass index, CVD Cardiovascular Disease, HDL High Density lipoprotein cholesterol, CRP C-reactive Protein, ETP endogenous thrombin potential